| |
| |
| Preface | |
| |
| |
| Preface to the First Edition | |
| |
| |
| |
| General Principles | |
| |
| |
| |
| Introduction | |
| |
| |
| |
| General Principles of Psychopharmacotherapy with Children and Adolescents | |
| |
| |
| Psychiatric Diagnosis and Psychopharmacotherapy | |
| |
| |
| Current Psychiatric Diagnostic Nomenclature | |
| |
| |
| Diagnosis and Target Symptoms | |
| |
| |
| Special Aspects of Child Psychopharmacotherapy | |
| |
| |
| Maturational/Developmental Issues | |
| |
| |
| Relationship to the Patient's Family or Caregivers | |
| |
| |
| Explaining Medication to the Child or Adolescent | |
| |
| |
| Medicolegal Aspects of Medicating Children and Adolescents | |
| |
| |
| Baseline Assessments Prior to Initiation of Medication | |
| |
| |
| Physical Examination | |
| |
| |
| Laboratory Tests and Diagnostic Procedures | |
| |
| |
| Baseline Behavioral Assessment | |
| |
| |
| Medicating the Patient: Selecting the Initial and Subsequent Medications | |
| |
| |
| Drug Interactions | |
| |
| |
| Regulating the Medication | |
| |
| |
| Adverse Effects (Side Effects) | |
| |
| |
| Monitoring of Serum Levels of Drugs and/or of Their Metabolites | |
| |
| |
| Length of Time to Continue Medication | |
| |
| |
| |
| Specific Drugs | |
| |
| |
| |
| Introduction | |
| |
| |
| Placebos | |
| |
| |
| Evaluating Research Studies | |
| |
| |
| Specific Drug Treatments | |
| |
| |
| |
| Sympathomimetic Amines and Central Nervous System Stimulants | |
| |
| |
| Introduction | |
| |
| |
| Methylphenidate and Attention-Deficit/Hyperactivity Disorder | |
| |
| |
| Pharmacokinetics of Stimulants | |
| |
| |
| Standard Stimulant Preparations Compared with Long-Acting or Sustained-Release Forms | |
| |
| |
| Contraindications for Stimulant Administration | |
| |
| |
| Interactions of Stimulants with Other Drugs | |
| |
| |
| Methylphenidate and Clonidine | |
| |
| |
| Adverse Effects of Stimulants | |
| |
| |
| Rebound Effects of Stimulants | |
| |
| |
| Stimulants' Relationship to Tics and Tourette's Disorder | |
| |
| |
| Stimulant Drugs Approved for Use in Child and Adolescent Psychiatry | |
| |
| |
| Methylphenidate Hydrochloride (Ritalin, Ritalin LA, Ritalin-SR, Methylin, Methylin ER, Metadate, Metadate ER, Concerta, Daytrana) | |
| |
| |
| Dexmethylphenidate Hydrochloride (Focalin; Focalin-XR) | |
| |
| |
| Amphetamine Sulfate: Dextroamphetamine Sulfate (Dexedrine); Mixed Amphetamine Salts (Adderall) | |
| |
| |
| Adderall | |
| |
| |
| Caffeine | |
| |
| |
| Magnesium Pemoline (Cylert) | |
| |
| |
| |
| First Generation/Typical Antipsychotic Drugs | |
| |
| |
| Introduction | |
| |
| |
| Antipsychotic Drugs in the Treatment of Attention-Deficit/Hyperactivity Disorders | |
| |
| |
| Pharmacokinetics of Antipsychotic Drugs | |
| |
| |
| Contraindications for the Administration of Antipsychotic Drugs | |
| |
| |
| Interactions of Antipsychotic Drugs with Other Medications | |
| |
| |
| Untoward Effects of Antipsychotic Drugs | |
| |
| |
| Agranulocytosis | |
| |
| |
| Untoward Cognitive Effects | |
| |
| |
| Extrapyramidal Syndromes | |
| |
| |
| Representative first generation/typical Antipsychotic Drugs | |
| |
| |
| Considerations About Dosage | |
| |
| |
| First Generation/typical Antipsychotic Drugs | |
| |
| |
| Chlorpromazine Hydrochloride (Thorazine) | |
| |
| |
| Thioridazine Hydrochloride (Mellaril) | |
| |
| |
| Trifluoperazine Hydrochloride (Stelazine, Vesprin) | |
| |
| |
| Haloperidol (Haldol) | |
| |
| |
| Thiothixene (Navane) | |
| |
| |
| Loxapine Succinate (Loxitane) | |
| |
| |
| Molindone Hydrochloride (Moban) | |
| |
| |
| Fluphenazine Hydrochloride (Prolixin, Permitil) | |
| |
| |
| Pimozide (Orap) | |
| |
| |
| |
| Second Generation/Atypical and Other Antipsychotic Drugs | |
| |
| |
| "Atypical" Antipsychotic Drugs | |
| |
| |
| Clozapine (Clozaril) | |
| |
| |
| Risperidone (Risperdal) | |
| |
| |
| Olanzapine (Zyprexa) | |
| |
| |
| Quetiapine Fumarate (Seroquel) | |
| |
| |
| Aripiprazole (Abilify) | |
| |
| |
| Ziprasidone Hydrochloride (Geodon) | |
| |
| |
| |
| Antidepressant Drugs | |
| |
| |
| Introduction | |
| |
| |
| Suicidal Risk and Antidepressants | |
| |
| |
| Tricyclic Antidepressants | |
| |
| |
| Indications for Tricyclic Antidepressants in Child and Adolescent Psychiatry | |
| |
| |
| Pharmacokinetics of Tricyclic Antidepressants | |
| |
| |
| Tricyclic Antidepressant Discontinuation/Withdrawal Syndrome | |
| |
| |
| Contraindications for Tricyclic Antidepressant Administration | |
| |
| |
| Interactions of Tricyclic Antidepressants with Other Drugs | |
| |
| |
| Untoward Effects of Tricyclic Antidepressants | |
| |
| |
| Tricyclic Antidepressants in Child and Adolescent Psychiatry | |
| |
| |
| Imipramine Hydrochloride (Tofranil), Imipramine Pamoate (Tofranil-PM) | |
| |
| |
| Nortriptyline Hydrochloride (Pamelor) | |
| |
| |
| Amitriptyline Hydrochloride (Elavil, Endep) | |
| |
| |
| Desipramine Hydrochloride (Norpramin, Pertofrane) | |
| |
| |
| Clomipramine Hydrochloride (Anafranil) | |
| |
| |
| Selective Serotonin Reuptake Inhibitors (SSRIs) | |
| |
| |
| Fluoxetine Hydrochloride (Prozac, Sarafem) | |
| |
| |
| Sertraline Hydrochloride (Zoloft) | |
| |
| |
| Paroxetine Hydrochloride (Paxil); Paroxetine Mesylate (Pexeva) | |
| |
| |
| Fluvoxamine Maleate (Luvox) | |
| |
| |
| Citalopram Hydrobromide (Celexa) | |
| |
| |
| Escitalopram Oxalate (Lexapro) | |
| |
| |
| Other Antidepressants | |
| |
| |
| Trazodone Hydrochloride (Desyrel) | |
| |
| |
| Bupropion Hydrochloride (Wellbutrin, Zyban) | |
| |
| |
| Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs) | |
| |
| |
| Venlafaxine Hydrochloride (Effexor) | |
| |
| |
| Mirtazapine (Remeron) | |
| |
| |
| Duloxetine Hydrochloride (Cymbalta) | |
| |
| |
| Selective Norepinephrine Reuptake Inhibitors (SNRIs) | |
| |
| |
| Atomoxetine Hydrochloride (Strattera) | |
| |
| |
| Monoamine Oxidase Inhibitors (MAOIs) | |
| |
| |
| Special Considerations in Using MAOIs | |
| |
| |
| Contraindications for Monoamine Oxidase Inhibitor Administration | |
| |
| |
| Interactions of MAOIs with Other Drugs | |
| |
| |
| Untoward Effects of MAOIs | |
| |
| |
| Reports of Interest | |
| |
| |
| |
| Mood Stabilizers: Lithium Carbonate and Antiepileptics | |
| |
| |
| Lithium Carbonate | |
| |
| |
| Pharmacokinetics of Lithium Carbonate | |
| |
| |
| Contraindications for Lithium Carbonate Administration | |
| |
| |
| Interactions of Lithium Carbonate with Other Drugs | |
| |
| |
| Lithium Toxicity | |
| |
| |
| Untoward Effects of Lithium Carbonate | |
| |
| |
| Premedication Workup and Periodic Monitoring for Lithium Treatment | |
| |
| |
| Periodic Monitoring | |
| |
| |
| Reports of Interest | |
| |
| |
| Antiepileptics/Mood Stabilizers | |
| |
| |
| Valproic Acid (Depakene); Divalproex Sodium (Valproic Acid and Valproate Sodium [Depakote; Depacon]) | |
| |
| |
| Carbamazepine (Tegretol; Carbatrol, Equetro) | |
| |
| |
| Phenytoin, Diphenylhydantoin (Dilantin) | |
| |
| |
| Gabapentin (Neurontin) | |
| |
| |
| Lamotrigine (Lamictal) | |
| |
| |
| Oxcarbazepine (Trileptal) | |
| |
| |
| Topiramate (Topamax) | |
| |
| |
| |
| Antianxiety Drugs | |
| |
| |
| Benzodiazepines | |
| |
| |
| Contraindications for Benzodiazepine Administration | |
| |
| |
| Interactions of Benzodiazepines with Other Drugs | |
| |
| |
| Untoward Effects of Benzodiazepines | |
| |
| |
| Use of Benzodiazepines in Child and Adolescent Psychiatry | |
| |
| |
| Chlordiazepoxide (Librium) | |
| |
| |
| Diazepam (Valium) | |
| |
| |
| Alprazolam (Xanax) | |
| |
| |
| Clonazepam (Klonopin) | |
| |
| |
| Azaspirodecanediones | |
| |
| |
| Buspirone Hydrochloride (Buspar) | |
| |
| |
| |
| Other Drugs | |
| |
| |
| Antihistamines | |
| |
| |
| Contraindications for Antihistamine Administration | |
| |
| |
| Interactions of Antihistamines with Other Drugs | |
| |
| |
| Diphenhydramine Hydrochloride (Benadryl) | |
| |
| |
| Hydroxyzine Hydrochloride (Atarax), Hydroxyzine Pamoate (Vistaril) | |
| |
| |
| Opiate Antagonists | |
| |
| |
| Naltrexone Hydrochloride (Trexan, Revia) | |
| |
| |
| Beta-Adrenergic Blockers | |
| |
| |
| Propranolol Hydrochloride (Inderal) | |
| |
| |
| Pindolol (Visken) | |
| |
| |
| Alpha-Adrenergic Agonists | |
| |
| |
| Clonidine Hydrochloride (Catapres), Clonidine (Catapres-Transdermal Therapeutic System) | |
| |
| |
| Guanfacine Hydrochloride (Tenex) | |
| |
| |
| Barbiturates and Hypnotics | |
| |
| |
| References | |
| |
| |
| Index | |